1. Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00395-w.
2. European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 16 Mar 2020.
3. US Food and Drug Administration. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009: guidance for industry. https://www.fda.gov/media/119258/download. Accessed 16 Mar 2020.
4. WHO Expert Committee on Biological Standardization—Technical Report Series 977: Annex 2—guidelines on evaluation of similar biotherapeutic products (SBPs). https://apps.who.int/medicinedocs/documents/s19941en/s19941en.pdf. Accessed 16 Mar 2020.
5. Winegarden W. Incenting competition to reduce drug spending: the biosimilar opportunity. Pacific Research Institute. 2019. https://www.pacificresearch.org/wp-content/uploads/2019/07/BiosimilarsCompetition_F.pdf. Accessed 16 Mar 2020.